Allergen immunotherapy: therapeutic vaccines for allergic diseases

ABBREVIATIONS AAAAI: American Academy of Allergy, Asthma and Immunology AU: Allergy Unit BAU: Bioequivalent Allergy Unit BU: Biologic Unit CBER: Center for Biologic Evaluation and Research EAACI: European Academy of Allergy and Clinical Immunology EU: European Union IAACI: International Association of Allergy and Clinical Immunology IU: International Unit IUIS: International Union of Immunological Societies PNU: protein nitrogen unit

[1]  V. Brusasco,et al.  Local immunotherapy with Dermatophagoides extract in asthma. , 1991, The Journal of allergy and clinical immunology.

[2]  K. Bagstad,et al.  Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. , 1994, Annals of allergy.

[3]  R. Panzani,et al.  Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen. , 1995, Journal of investigational allergology & clinical immunology.

[4]  L. Espinoza,et al.  Digital vasculitis following allergic desensitization treatment. , 1993, The Journal of rheumatology.

[5]  S. Dreborg,et al.  Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis , 1994, Allergy.

[6]  E. Sercarz,et al.  Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity , 1996, The Journal of experimental medicine.

[7]  C. Dolecek,et al.  Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. , 1997, The Journal of allergy and clinical immunology.

[8]  J. Deighton,et al.  Bee venom immunotherapy induces a shift in cytokine responses from a TH‐2 to a TH‐1 dominant pattern: comparison of rush and conventional immunotherapy , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  G. Senna,et al.  Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. , 1993, The Journal of allergy and clinical immunology.

[10]  J. Banchereau,et al.  Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. , 1996, Journal of immunology.

[11]  A. Kagey‐Sobotka,et al.  Immunotherapy for cat asthma. , 1988, The Journal of allergy and clinical immunology.

[12]  R. Lockey,et al.  Venom immunotherapy in the Hymenoptera-allergic pregnant patient. , 1990, The Journal of allergy and clinical immunology.

[13]  R. Puy,et al.  Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. , 1995, American journal of respiratory and critical care medicine.

[14]  R. Djurup,et al.  High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens , 1987, Clinical allergy.

[15]  S. Tarlo,et al.  Allergen injection therapy with glutaraldehyde-modified--ragweed pollen-tyrosine adsorbate. A double-blind trial. , 1977, The Journal of allergy and clinical immunology.

[16]  T. Rafnar,et al.  Molecular identification of an IgE-dependent histamine-releasing factor. , 1995, Science.

[17]  R. Patterson,et al.  Modified forms of allergen immunotherapy. , 1985, The Journal of allergy and clinical immunology.

[18]  R. Reisman,et al.  Clinical and immunological studies of venom immunotherapy , 1979, Clinical allergy.

[19]  J. Bousquet,et al.  Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. , 1991, The Journal of allergy and clinical immunology.

[20]  R. Dahl,et al.  A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. , 1993, The Journal of allergy and clinical immunology.

[21]  J. Flinterman,et al.  Hyposensitisation to wasp venom in six hours. , 1983, British medical journal.

[22]  A. Blanco‐quirós,et al.  Rush immunotherapy with a standardized Bermuda grass pollen extract. , 1989, Annals of allergy.

[23]  Flemming M. Poulsen,et al.  X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy , 1996, Nature Structural Biology.

[24]  R. Einarsson,et al.  Cat (Fel d I), dog (Can f I), and cockroach allergens in homes of asthmatic children from three climatic zones in Sweden , 1994, Allergy.

[25]  M. Breitenbach,et al.  Evaluation of immunotherapy‐induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting , 1990, Allergy.

[26]  L. Lichtenstein,et al.  A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. , 1980, The Journal of allergy and clinical immunology.

[27]  K. B. Hafner,et al.  Treatment of cat allergy with T-cell reactive peptides. , 1996, American journal of respiratory and critical care medicine.

[28]  F. C. Lowell,et al.  Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. , 1978, The Journal of allergy and clinical immunology.

[29]  M. Abramson,et al.  Ragweed immunotherapy in adult asthma. , 1996, The New England journal of medicine.

[30]  J. Jones,et al.  Effect of mixing allergenic extracts containing Helminthosporium, D. farinae, and cockroach with perennial ryegrass. , 1993, Annals of allergy.

[31]  J. D. de Vries,et al.  Immunoregulatory properties of IL-13: its potential role in atopic disease. , 1995, International archives of allergy and immunology.

[32]  C. Richart,et al.  Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. , 1993, Chest.

[33]  A. McWilliam,et al.  Production of multilamellar, small unilamellar and reverse-phase liposomes containing house dust mite allergens. Potential adjuvants in the immunotherapy of allergic disease. , 1989, Journal of immunological methods.

[34]  G. Gleich,et al.  Measurement of the potency of allergy extracts by their inhibitory capacities in the radioallergosorbent test. , 1974, The Journal of allergy and clinical immunology.

[35]  J. Georgitis,et al.  Local nasal immunotherapy: efficacy of low-dose aqueous ragweed extract. , 1985, The Journal of allergy and clinical immunology.

[36]  E. Juniper,et al.  International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. , 1994, Allergy.

[37]  J. Bousquet,et al.  Immunotherapy with Hymenoptera venoms , 1987, Allergy.

[38]  R. de Waal Malefyt,et al.  IL-12 transiently induces IFN-gamma transcription and protein synthesis in human CD4+ allergen-specific Th2 T cell clones. , 1994, International immunology.

[39]  R. Lockey,et al.  Survey of fatalities from skin testing and immunotherapy 1985-1989. , 1993, The Journal of allergy and clinical immunology.

[40]  C. Ebner,et al.  Booster immunotherapy (BIT) , 1994, Allergy.

[41]  H. Malling,et al.  Clustered Immunotherapy with Yellow Jacket Venom , 1985, Allergy.

[42]  J. Bousquet,et al.  Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. , 1991, The Journal of allergy and clinical immunology.

[43]  H. Kerstjens,et al.  Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. , 1995, American journal of respiratory and critical care medicine.

[44]  W. Aberer,et al.  Reduction of side effects of specific immunotherapy by premedication with antihistaminics and reduction of maximal dosage to 50.000 SQ-U/ml. , 1988, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.

[45]  R. Naclerio,et al.  Responses to ragweed-pollen nasal challenge before and after immunotherapy. , 1989, The Journal of allergy and clinical immunology.

[46]  J. Lamb,et al.  Induction of non-responsiveness in human allergen-specific type 2 T helper cells. , 1994, Current opinion in immunology.

[47]  H. Mosbech,et al.  Does the effect of immunotherapy last after termination of treatment? , 1988, Allergy.

[48]  P. Phanuphak,et al.  Onset of polyarteritis nodosa during allergic hyposensitization treatment. , 1980, The American journal of medicine.

[49]  P. Norman.  International units. , 2020, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.

[50]  S. Goldstein,et al.  Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response. , 1981, The Journal of allergy and clinical immunology.

[51]  M. Cazzola,et al.  A double‐blind, placebo‐controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[52]  E. Assem,et al.  House-dust Mite Asthma. Results of Challenge Tests on Five Criteria with Dermatophagoides pteronyssinus , 1970, British medical journal.

[53]  R. Thompson.  The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. , 1989, Allergy.

[54]  S. Durham,et al.  Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. , 1993, The Journal of clinical investigation.

[55]  R. Aalberse,et al.  The role of IgG in immediate-type hypersensitivity. , 1991, The European respiratory journal. Supplement.

[56]  H. Løwenstein.  Report on behalf of the International Union of Immunological Societies (I.U.I.S.) Allergen Standardization Subcommittee. , 1983, Arbeiten aus dem Paul-Ehrlich-Institut, dem Georg-Speyer-Haus und dem Ferdinand-Blum-Institut zu Frankfurt a.M.

[57]  H. Weiner,et al.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. , 1993, Science.

[58]  D. Hughes,et al.  Controlled trial of a home and ambulatory program for asthmatic children. , 1991, Pediatrics.

[59]  H. Fujita,et al.  Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin , 1983, The Journal of experimental medicine.

[60]  W. Pierson,et al.  The waiting period after allergen skin testing and immunotherapy. American Academy of Allergy and Immunology. , 1990, The Journal of allergy and clinical immunology.

[61]  R. Reisman,et al.  Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses. , 1992, The Journal of allergy and clinical immunology.

[62]  A. Helbling,et al.  Predictive value of venom‐specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom , 1989, Allergy.

[63]  G. Gleich,et al.  Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. , 1982, The Journal of allergy and clinical immunology.

[64]  P. Norman.  Is there a role for immunotherapy in the treatment of asthma? Yes. , 1996, American journal of respiratory and critical care medicine.

[65]  G. Passalacqua,et al.  A three‐year double‐blind placebo‐controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[66]  B. Chatterjee,et al.  Placebo-controlled immunotherapy with Cocos nucifera pollen extract. , 1994, International archives of allergy and immunology.

[67]  J. Tonascia,et al.  A controlled trial of immunotherapy for asthma in allergic children. , 1997, The New England journal of medicine.

[68]  J. Georgitis,et al.  Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. , 1984, The Journal of allergy and clinical immunology.

[69]  U. Müller,et al.  Reduction of side effects from rush‐immunotherapy with honey bee venom by pretreatment with terfenadine , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[70]  S. Durham,et al.  Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. , 1996, The Journal of allergy and clinical immunology.

[71]  J. Bousquet,et al.  Anti-IgE therapy for asthma. , 1997, American journal of respiratory and critical care medicine.

[72]  R. Naclerio,et al.  Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. , 1991, The Journal of allergy and clinical immunology.

[73]  M. Turner,et al.  Failure of hyposensitisation in treatment of children with grass-pollen asthma , 1982, British medical journal.

[74]  S. Quirce,et al.  A prospective safety‐monitoring study of immunotherapy with biologically standardized extracts , 1993, Allergy.

[75]  A. Kagey‐Sobotka,et al.  Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. , 1982, The Journal of allergy and clinical immunology.

[76]  S. Mohapatra.  Recombinant allergens and allergen standardization. , 1992, The Journal of allergy and clinical immunology.

[77]  J. Bousquet,et al.  Differences in IL-4 release by PBMC are related with heterogeneity of atopy. , 1994, Immunology.

[78]  J. Georgitis,et al.  Local intranasal immunotherapy with high-dose polymerized ragweed extract. , 1986, International archives of allergy and applied immunology.

[79]  K. Arai,et al.  IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[80]  K. Hoffmann‐Sommergruber,et al.  Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy , 1996, The Journal of experimental medicine.

[81]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[82]  H. Chai,et al.  Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy. , 1988, The Journal of allergy and clinical immunology.

[83]  G. Hedlin,et al.  Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. , 1986, The Journal of allergy and clinical immunology.

[84]  P. Barnes.  Is there a role for immunotherapy in the treatment of asthma? No. , 1996, American journal of respiratory and critical care medicine.

[85]  S. Voltolini,et al.  Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. , 1995, Journal of investigational allergology & clinical immunology.

[86]  J. Warner,et al.  Hyposensitisation with house dust mite vaccine in bronchial asthma. , 1976, British medical journal.

[87]  E. Perrin,et al.  Parental perceptions of health status and psychologic adjustment of children with asthma. , 1989, Pediatrics.

[88]  L. Hellman.  Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine , 1994, European journal of immunology.

[89]  P. Ventas,et al.  Immunotherapy with the storage mite lepidoglyphus destructor. , 1995, Allergologia et immunopathologia.

[90]  R. Djurup,et al.  Oral Administration of Grass Pollen to Hay Fever Patients , 1985, Allergy.

[91]  R. Einarsson,et al.  The major allergen content of allergenic preparations reflects their biological activity , 1992, Allergy.

[92]  A. Elbers,et al.  The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy. , 1996, The Journal of allergy and clinical immunology.

[93]  P. Venge,et al.  Eosinophil chemotactic activity in allergic patients during the birch pollen season: the effect of immunotherapy. , 1987, International Archives of Allergy and Applied Immunology.

[94]  S. A. O'Connor,et al.  Compliance with prescribed drug therapy in asthma. , 1994, Respiratory medicine.

[95]  L. Lichtenstein,et al.  A controlled trial of immunotherapy in insect hypersensitivity. , 1978, The New England journal of medicine.

[96]  D. Haustein,et al.  ZWISCHENFALLE NACH HYPOSENSIBILISIERUNG , 1996 .

[97]  J. Bousquet,et al.  Safety of venom immunotherapy administered by a cluster schedule. , 1992, The Journal of allergy and clinical immunology.

[98]  B. Björkstén,et al.  Oral immunotherapy in birch pollen hay fever. , 1987, The Journal of allergy and clinical immunology.

[99]  I. Bernstein,et al.  Clinical and immunologic studies of rapid venom immunotherapy in Hymenoptera-sensitive patients. , 1989, The Journal of allergy and clinical immunology.

[100]  S. Hauser,et al.  Late Complications of Immune Deviation Therapy in a Nonhuman Primate , 1996, Science.

[101]  P. Ewan,et al.  Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite , 1988, Clinical allergy.

[102]  G. Pauli,et al.  Celery sensitivity: clinical and immunological correlations with pollen allergy , 1985, Clinical allergy.

[103]  F. Shakib,et al.  In vitro basophil histamine‐releasing activity of circulating IgG1 and IgG4 autoanti‐IgE antibodies from asthma patients and the demonstration that anti‐IgE modulates allergen‐induced basophil activation , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[104]  R. Einarsson,et al.  Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. , 1989, Annals of allergy.

[105]  L. Lichtenstein,et al.  IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. , 1973, The Journal of clinical investigation.

[106]  G. Senna,et al.  Local nasal immunotherapy for birch allergic rhinitis with extract in powder form , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[107]  H. Van Bever,et al.  Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. , 1990, The Journal of allergy and clinical immunology.

[108]  B. Björkstén,et al.  Local immunotherapy is not documented for clinical use , 1994, Allergy.

[109]  R. Aalberse,et al.  Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. , 1983, Journal of immunology.

[110]  H. Pence,et al.  Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. , 1976, The Journal of allergy and clinical immunology.

[111]  A. Helbling,et al.  Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. , 1991, The Journal of allergy and clinical immunology.

[112]  M. Fernández-Figueras,et al.  Persistent subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. , 1995, Archives of dermatology.

[113]  J. Bousquet,et al.  Clinical and immunologic survey in beekeepers in relation to their sensitization. , 1984, The Journal of allergy and clinical immunology.

[114]  R. Patterson,et al.  A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. , 1983, The Journal of allergy and clinical immunology.

[115]  G. Schultze-Werninghaus,et al.  A manufacturer's criteria for in-house reference preparations for RAST inhibition. , 1987, Annals of allergy.

[116]  D. Kraft,et al.  Basic and practical aspects of recombinant allergens , 1995, Allergy.

[117]  R. Naclerio,et al.  Allergic and Non-Allergic Rhinitis: Clinical Aspects , 1993 .

[118]  O. ØSterballe,et al.  IgG Subclass Antibody Response in Grass Pollen‐Allergic Patients Undergoing Specific Immunotherapy , 1984, Allergy.

[119]  J. Bousquet,et al.  Combination of passive and active immunization in honeybee venom immunotherapy. , 1987, The Journal of allergy and clinical immunology.

[120]  C. Dolecek,et al.  Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). , 1996, The Journal of allergy and clinical immunology.

[121]  M. Jutel,et al.  Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[122]  S. Dreborg,et al.  Diagnosis and immunotherapy of mould allergy , 1987, Allergy.

[123]  E. Hey,et al.  CONTROLLED TRIAL OF HYPOSENSITISATION TO DERMATOPHAGOIDES PTERONYSSINUS IN CHILDREN WITH ASTHMA , 1978, The Lancet.

[124]  F. Guerra,et al.  Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. , 1994, Journal of investigational allergology & clinical immunology.

[125]  S. Burgers,et al.  Hymenoptera sting challenge of 348 patients: relation to subsequent field stings. , 1996, The Journal of allergy and clinical immunology.

[126]  E. Pastorello,et al.  A double‐blind, placebo‐controlled study of immunotherapy with an alginate‐conjugated extract of Parietaria Judaica in patients with Parietaria hay fever , 1994, Allergy.

[127]  J. Kelso,et al.  Oral allergy syndrome successfully treated with pollen immunotherapy. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[128]  K. Larsen,et al.  A 1‐year, placebo‐controlled, double‐blind house‐dust‐mite immunotherapy study in asthmatic adults , 1997, Allergy.

[129]  W. Heath,et al.  Induction of Autoimmune Diabetes by Oral Administration of Autoantigen , 1996, Science.

[130]  A. Helbling,et al.  Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. , 1992, The Journal of allergy and clinical immunology.

[131]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. , 1990, The Journal of allergy and clinical immunology.

[132]  C. V. van Niekerk,et al.  Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study. , 1987, Clinical allergy.

[133]  D. Marsh,et al.  The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract. , 1985, The Journal of allergy and clinical immunology.

[134]  A. Frew.  Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. , 1993, BMJ.

[135]  M. Megson,et al.  Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects , 1973, Clinical allergy.

[136]  A. Frankland,et al.  Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. , 1954, Lancet.

[137]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. , 1990, The Journal of allergy and clinical immunology.

[138]  M. McAllen.  HYPOSENSITISATION IN GRASS POLLEN HAY FEVER , 1969, Acta allergologica.

[139]  M. Weinstock,et al.  Studies in pollen allergy. 3. The relationship between blocking antibody levels and symptomatic relief following hyposensitisation with allpyral in hay fever subjects. , 1970, International archives of allergy and applied immunology.

[140]  J. Banchereau,et al.  IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. , 1988, Journal of immunology.

[141]  Shau-ku Huang,et al.  Immunoprophylaxis of allergen–induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization , 1996, Nature Medicine.

[142]  J. Bousquet,et al.  Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. , 1988, The Journal of allergy and clinical immunology.

[143]  J. H. Barnard.  Studies of 400 hymenoptera sting deaths , 1973 .

[144]  A. Sabbah,et al.  A double‐blind, placebo‐controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract , 1994, Allergy.

[145]  G. Hedlin,et al.  Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. , 1986, The Journal of allergy and clinical immunology.

[146]  R. Lockey,et al.  Fatalities from immunotherapy (IT) and skin testing (ST) , 1987, The Journal of allergy and clinical immunology.

[147]  L. Lichtenstein,et al.  The clinical and immunologic specificity of immunotherapy. , 1978, The Journal of allergy and clinical immunology.

[148]  M. Glover,et al.  A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[149]  H. Mosbech,et al.  High dose grass pollen tablets used for hyposensitization in hay fever patients , 1987, Allergy.

[150]  R. Jones,et al.  Rush venom immunotherapy program for honeybee sting sensitivity. , 1979, The Journal of allergy and clinical immunology.

[151]  M. Mancino,et al.  Immunotherapy by inhalation of allergen in powder in house dust allergic asthma--a double-blind study. , 1992, Journal of investigational allergology & clinical immunology.

[152]  J. Bousquet,et al.  Systemic reactions during maintenance immunotherapy with honey bee venom. , 1988, Annals of allergy.

[153]  E. Noguchi,et al.  IgE responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2. , 1996, International archives of allergy and immunology.

[154]  M. Reid,et al.  Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. , 1986, Annals of allergy.

[155]  J. Bousquet,et al.  Systemic reactions occurring during immunotherapy with standardized pollen extracts. , 1992, The Journal of allergy and clinical immunology.

[156]  J. Bousquet,et al.  Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. , 1994, The Journal of allergy and clinical immunology.

[157]  H. Okudaira,et al.  A basic policy for allergen standardization in our country and standardization of Japanese cedar (Cryptomeria japonica) pollen extracts , 1997 .

[158]  B. Weeke,et al.  Position Paper: Immunotherapy , 1993, Allergy.

[159]  H. Mosbech,et al.  Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract , 1989, Allergy.

[160]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[161]  J. Bousquet,et al.  Current trends in the management of allergic diseases , 1994, Allergy.

[162]  R. Naclerio,et al.  Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. , 1985, The Journal of clinical investigation.

[163]  Asthma.  The use of standardized allergen extracts , 1997 .

[164]  D. Ownby,et al.  The appropriate use of skin testing and allergen immunotherapy in young children. , 1994, The Journal of allergy and clinical immunology.

[165]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[166]  O. Zetterström,et al.  Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever. , 1979, International archives of allergy and applied immunology.

[167]  The Inverse Association Between Tuberculin Responses and Atopic Disorder , 1997, Science.

[168]  H. Mcdevitt,et al.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. , 1995, Immunology today.

[169]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[170]  M. Chapman,et al.  Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. , 1996, Molecular immunology.

[171]  J. Bousquet,et al.  Specific immunotherapy in asthma: is it effective? , 1994, The Journal of allergy and clinical immunology.

[172]  J. Bernhisel-Broadbent.  Allergenic cross-reactivity of foods and characterization of food allergens and extracts. , 1995, Annals of Allergy, Asthma & Immunology.

[173]  E. Sala,et al.  Preseasonal intranasal immunotherapy in birch‐alder allergic rhinitis: A double‐blind study , 1996, Allergy.

[174]  H. Ipsen,et al.  Immunotherapy with partially purified and standardized tree pollen extracts , 1988, Allergy.

[175]  E. Pastorello,et al.  Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. , 1984, The Journal of allergy and clinical immunology.

[176]  J. Greenstein,et al.  Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[177]  H. Jansen,et al.  Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests. , 1996, International archives of allergy and immunology.

[178]  D. Kemeny,et al.  A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. , 1990, The Journal of allergy and clinical immunology.

[179]  J. Cuesta-Herranz,et al.  Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. , 1994, The Journal of allergy and clinical immunology.

[180]  P. Norman.  WHO-IUIS International Standards: advantages of these extracts. , 1994, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.

[181]  D. Ikle,et al.  Studies of allergen extract stability: the effects of dilution and mixing. , 1996, The Journal of allergy and clinical immunology.

[182]  R. Valenta,et al.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. , 1997, The Journal of clinical investigation.

[183]  J. Kalbfleisch,et al.  Comparison of Rinkel injection therapy with standard immunotherapy. , 1982, The Journal of allergy and clinical immunology.

[184]  B. Björkstén,et al.  Oral Immunotherapy of Children with Rhinoconjunctivitis due to Birch Pollen Allergy A Double Blind Study , 1986, Allergy.

[185]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[186]  D. Golden,et al.  Regimens of Hymenoptera venom immunotherapy. , 1980, Annals of internal medicine.

[187]  E. Pastorello,et al.  A double‐blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac®) in patients with perennial rhinitis , 1989 .

[188]  R. Lockey,et al.  The Hymenoptera venom study. III: Safety of venom immunotherapy. , 1990, The Journal of allergy and clinical immunology.

[189]  H. Nelson,et al.  A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. , 1993, The Journal of allergy and clinical immunology.

[190]  R. Valenta,et al.  Construction of a Combinatorial IgE Library from an Allergic Patient , 1996, The Journal of Biological Chemistry.

[191]  M. Grieco,et al.  The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. , 1986, Annals of allergy.

[192]  F. C. Lowell,et al.  A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. , 1965, The New England journal of medicine.

[193]  L. Lichtenstein,et al.  Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. , 1981, The Journal of allergy and clinical immunology.

[194]  A. Frew,et al.  Position Paper: Allergen standardization and skin tests , 1993 .

[195]  J. Bousquet,et al.  Evolution of sensitivity to Hymenoptera venom in 200 allergic patients followed for up to 3 years. , 1989, The Journal of allergy and clinical immunology.

[196]  G. Barratt,et al.  Optimization and characterization of freeze‐dried multilamellar liposomes incorporating different standardized allergen extracts , 1994, Allergy.

[197]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. , 1996, Allergy.

[198]  L. Noon.  Prophylactic inoculation against hay fever. , 1911, International archives of allergy and applied immunology.

[199]  R. Valenta,et al.  Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). , 1995, The Journal of allergy and clinical immunology.

[200]  P. Yarnold,et al.  An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[201]  T. Kristensen,et al.  Immunotherapy with dog and cat extracts in children , 1989, Allergy.

[202]  B. Wallaert,et al.  CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[203]  R. Webster,et al.  DNA vaccines. , 1996, AIDS research and human retroviruses.

[204]  M. Lombardero,et al.  New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. , 1994, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.

[205]  P. Venge,et al.  The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. , 1988, The Journal of allergy and clinical immunology.

[206]  D. Meyers,et al.  Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. , 1982, Journal of Allergy and Clinical Immunology.

[207]  L. Lichtenstein,et al.  The role of ragweed pollen in autumnal asthma. , 1977, The Journal of allergy and clinical immunology.

[208]  M. Nielsen,et al.  Persistent Subcutaneous Nodules in Children Hyposensitized with Aluminium‐Containing Allergen Extracts , 1985, Allergy.

[209]  G. Gleich,et al.  Preseasonal intranasal immunotherapy with nebulized short ragweed extract. , 1981, The Journal of allergy and clinical immunology.

[210]  S. Findlay,et al.  Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. , 1984, The Journal of allergy and clinical immunology.

[211]  P. Gergen,et al.  An economic evaluation of asthma in the United States. , 1992, The New England journal of medicine.

[212]  A. Dubois,et al.  Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. , 1994, The Journal of allergy and clinical immunology.

[213]  N. Egen,et al.  Rate and quantity of delivery of venom from honeybee stings. , 1994, The Journal of allergy and clinical immunology.

[214]  S. Pedersen.  Ensuring compliance in children. , 1992, The European respiratory journal.

[215]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. , 1989, The Journal of allergy and clinical immunology.

[216]  M. Kampelmacher,et al.  Provocation test with a living insect as a diagnostic tool in systemic reactions to bee and wasp venom: a prospective study with emphasis on the clinical aspects , 1987, Clinical allergy.

[217]  S. Rastogi,et al.  A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. , 1982, The Journal of allergy and clinical immunology.

[218]  G. Pauli,et al.  Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. , 1984, The Journal of allergy and clinical immunology.

[219]  L. Lichtenstein,et al.  Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals. , 1971, The Journal of allergy.

[220]  R. Valenta,et al.  Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. , 1992, The Journal of allergy and clinical immunology.

[221]  R. Lockey,et al.  Allergens of the imported fire ant. , 1988, The Journal of allergy and clinical immunology.

[222]  G. Senna,et al.  Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. , 1996, The Journal of allergy and clinical immunology.

[223]  A. Blainey,et al.  Hyposensitization with a Tyrosine Adsorbed Extract of Dermatophagoides pteronyssinus in Adults with Perennial Rhinitis , 1984, Allergy.

[224]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. , 1987, The Journal of allergy and clinical immunology.

[225]  J. Salvaggio,et al.  Postgraduate course presentations. Mold-induced asthma. , 1981, The Journal of allergy and clinical immunology.

[226]  R. Naclerio,et al.  Comparison of the in‐vivo and in‐vitro response to ragweed immunotherapy in children and adults with ragweed‐induced rhinitis , 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[227]  J. Darbyshire,et al.  A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children , 1984, Clinical allergy.

[228]  H. Nelson,et al.  Safety and efficacy of oral immunotherapy with standardized cat extract. , 1994, The Journal of allergy and clinical immunology.

[229]  M. Jutel,et al.  Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. , 1995, Journal of immunology.

[230]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. , 1997, The Journal of allergy and clinical immunology.

[231]  C. Franco,et al.  A double-blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. , 1995, Allergologia et immunopathologia.

[232]  R. Webster,et al.  DNA vaccines: a novel approach to immunization. , 1995, International journal of immunopharmacology.

[233]  R. Moss,et al.  Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. , 1986, The Journal of allergy and clinical immunology.

[234]  J. Kalbfleisch,et al.  Rinkel injection therapy: a multicenter controlled study. , 1981, The Journal of allergy and clinical immunology.

[235]  H. Løwenstein,et al.  Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long‐term (6‐year) follow‐up , 1997, Allergy.

[236]  M. Cazzola,et al.  Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: a two year double‐blind placebo‐controlled study , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[237]  L. Lichtenstein,et al.  Sensitization following Hymenoptera whole body extract therapy. , 1978, The Journal of allergy and clinical immunology.

[238]  L. Lichtenstein,et al.  A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. , 1968, Journal of immunology.

[239]  E. Juniper,et al.  Polyethylene glycol-modified ragweed extract: comparison of two treatment regimens. , 1986, The Journal of allergy and clinical immunology.

[240]  R. Summers,et al.  Late systemic-allergic reactions to inhalant allergen immunotherapy. , 1988, The Journal of allergy and clinical immunology.

[241]  O. Østerballe.  Side Effects during Immunotherapy with Purified Grass Pollen Extracts , 1982 .

[242]  S. Durham,et al.  Immunotherapy and allergic inflammation , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[243]  W. Thomas,et al.  Characterization of T-cell responses to the house dust mite allergen Der p II in mice. Evidence for major and cryptic epitopes. , 1993, Immunology.

[244]  J. Janosky,et al.  Compliance with allergen immunotherapy. , 1993, Annals of allergy.

[245]  J. Cohn,et al.  Determinants of patient compliance with allergen immunotherapy. , 1993, The Journal of allergy and clinical immunology.

[246]  I. Kobayashi,et al.  Differences in titres of IgE, IgG4 and other IgG subclass anti‐ Der p 2 antibodies in allergic and non‐allergic patients measured with recombinant allergen , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[247]  W. Aberer,et al.  Adrenaline for emergency kits. , 1995, Allergy.

[248]  B. Björkstén,et al.  High anti‐IgE levels at birth are associated with a reduced allergy prevalence in infants at risk: a prospective study , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[249]  H. Nelson.  Effect of preservatives and conditions of storage on the potency of allergy extracts. , 1981, The Journal of allergy and clinical immunology.

[250]  R. Reisman,et al.  Immunotherapy with antigen E. , 1969, The Journal of allergy.

[251]  R. Dahl,et al.  Immunotherapy in patients allergic to cat and dog dander , 1992, Allergy.

[252]  M. Raška,et al.  Allergen standardization. , 2000, Acta Universitatis Palackianae Olomucensis Facultatis Medicae.

[253]  T. Mahr,et al.  Allergist influence on asthma care. , 1993, Annals of allergy.

[254]  J. Bousquet,et al.  Clinical use of recombinant allergens and epitopes. , 1996, Advances in experimental medicine and biology.

[255]  S. Miescher,et al.  Can active immunization redirect an anti-IgE immune response? , 1997, International archives of allergy and immunology.

[256]  J. Bousquet,et al.  Specific immunotherapy in house dust mite allergy , 1995, Clinical reviews in allergy & immunology.

[257]  G. Senna,et al.  Local nasal immunotherapy in allergic rhinitis to Parietaria , 1992, Allergy.

[258]  G. Pauli,et al.  Grass Pollen Hyposensitization versus Placebo Therapy , 1981, Allergy.

[259]  G. Eisenbarth,et al.  Insulin prophylaxis in individuals at high risk of type 1 diabetes , 1993, The Lancet.

[260]  P. Norman.  Safety of allergen immunotherapy. , 1989, The Journal of allergy and clinical immunology.

[261]  K. Citron,et al.  Inhalation Tests of Bronchial Hypersensitivity in Pollen Asthma , 1958, Thorax.

[262]  D. Umetsu,et al.  Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type , 1995, The Journal of experimental medicine.

[263]  G. Hedlin,et al.  Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. , 1991, The Journal of allergy and clinical immunology.

[264]  D. Golden,et al.  Prolonged maintenance interval in hymenoptera venom immunotherapy. , 1981, The Journal of allergy and clinical immunology.

[265]  P. Venge,et al.  Soluble markers of allergic inflammation , 1994, Allergy.

[266]  H. Mosbech,et al.  The sting challenge test in Hymenoptera venom allergy Position paper of the subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology , 1996, Allergy.

[267]  R. Avila,et al.  Results of a clinical trial with a Dermatophagoides pteronyssinus tyrosine adsorbed vaccine. , 1978, Allergologia et immunopathologia.

[268]  W. Pichler,et al.  Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity , 1997, Allergy.

[269]  G. Hedlin,et al.  Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. , 1995, The Journal of allergy and clinical immunology.

[270]  J. Dry,et al.  Blocking IgG antibodies after rush immunotherapy with mites. , 1986, Annals of allergy.

[271]  C. Reed,et al.  Quality assurance and standardization of allergy extracts in allergy practice. , 1989, The Journal of allergy and clinical immunology.

[272]  R. Patterson,et al.  Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. , 1984, The Journal of allergy and clinical immunology.

[273]  D. Golden,et al.  Discontinuing venom immunotherapy: outcome after five years. , 1996, The Journal of allergy and clinical immunology.

[274]  M C Swanson,et al.  Allergen-specific IgG1 and IgG3 through Fc gamma RII induce eosinophil degranulation. , 1995, The Journal of clinical investigation.

[275]  L. Sandvik,et al.  Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four‐grass pollen mixture respectively , 1983, Clinical allergy.

[276]  H. Malling,et al.  Basophil Histamine Release and Humoral Changes during Immunotherapy , 1982, Allergy.

[277]  K. Ohta,et al.  IgG1 antibodies to house dust mite (Dermatophagoides farinae) and late asthmatic response. , 1986, International archives of allergy and applied immunology.

[278]  M. Gajhede,et al.  BIRCH POLLEN ALLERGEN BET V 1 , 1997 .

[279]  R. Reisman,et al.  HYPOSENSITIZATION THERAPY INCLUDING REPOSITORY: A DOUBLE-BLIND STUDY. , 1964, The Journal of allergy.

[280]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. , 1988, The Journal of allergy and clinical immunology.

[281]  R. Patterson,et al.  A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. , 1982, The Journal of allergy and clinical immunology.

[282]  R. Patterson,et al.  A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. , 1986, The Journal of allergy and clinical immunology.

[283]  J. Saint-Remy,et al.  Allergen‐antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen, hypersensitive patients , 1991, Allergy.

[284]  H. Nelson,et al.  Treatment of peanut allergy with rush immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[285]  S. Spector,et al.  Practice parameters for allergen immunotherapyabcde , 1996 .

[286]  E. E. Max,et al.  Alternative RNA of epsilon transcripts produces mRNAs encoding two membrane and four secreted IgE isoforms. , 1995, International Archives of Allergy and Immunology.

[287]  M. Guinnepain,et al.  Rush venom immunotherapy: a 3‐day programme for hymenoptera sting allergy , 1984, Clinical allergy.

[288]  A. Walls.  Liposomes for allergy immunotherapy? , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[289]  S. Dreborg,et al.  Cross‐reactivity between deciduous trees during immunotherapy. I. In vivo results , 1986, Clinical allergy.

[290]  A. Cantani,et al.  A three year controlled study in children with pollinosis treated with immunotherapy. , 1984, Annals of allergy.

[291]  小林 一郎.  IgE and IgG[4] antibodies from patients with mite allergy recognize different epitopes of Dermatophagoides pteronyssinus group II antigen (Der p 2) , 1996 .

[292]  D. Golden,et al.  Dose dependence of Hymenoptera venom immunotherapy. , 1981, The Journal of allergy and clinical immunology.

[293]  L. Lichtenstein,et al.  Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. , 1968, The American journal of medicine.

[294]  E. Raz,et al.  Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[295]  G. Aversa,et al.  Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13. , 1995, Journal of immunology.

[296]  U. Wahn,et al.  Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. , 1988, The Journal of allergy and clinical immunology.

[297]  C. Akdis,et al.  Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. , 1996, The Journal of clinical investigation.

[298]  R. Lockey,et al.  Systemic reactions from allergen immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[299]  R. Nathan,et al.  Effect of allergy specialist care on the quality of life in patients with asthma. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[300]  R. Reisman.  Should routine measurements of serum venom-specific IgG be a standard of practice in patients receiving venom immunotherapy? , 1992, The Journal of allergy and clinical immunology.

[301]  E. Hey,et al.  A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects , 1984, Clinical allergy.

[302]  S. Miescher,et al.  Domain-specific anti-IgE antibodies interfere with IgE binding to Fc epsilon RII. , 1994, International archives of allergy and immunology.

[303]  G. Gleich,et al.  Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. , 1983, The Journal of allergy and clinical immunology.

[304]  M. Mancino,et al.  Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. , 1990, Allergologia et immunopathologia.

[305]  J. Bousquet,et al.  Asthma: a disease remodeling the airways , 1992, Allergy.

[306]  L. Rosenhall,et al.  High Dose Inhaled Budesonide in the Treatment of Severe Steroid‐Dependent Asthmatics , 1985, Allergy.

[307]  A Jaramillo,et al.  Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice , 1993, The Journal of experimental medicine.

[308]  H. Weiner,et al.  Effects of oral administration of type II collagen on rheumatoid arthritis. , 1993, Science.

[309]  H. K. Ng,et al.  Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis , 1977, Clinical allergy.

[310]  S. Dreborg,et al.  A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. , 1987, The Journal of allergy and clinical immunology.

[311]  G. Hedlin,et al.  Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. , 1989, The Journal of allergy and clinical immunology.

[312]  E. Valovirta,et al.  Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. , 1986, Annals of allergy.

[313]  D. Umetsu,et al.  Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals , 1993, The Journal of experimental medicine.

[314]  E. Åkerblom,et al.  Immunotherapy with monomethoxypolyethylene glycol modified allergens. , 1990, Critical reviews in therapeutic drug carrier systems.

[315]  J. Bousquet,et al.  Safety Considerations in Assessing the Role of Immunotherapy in Allergic Disorders , 1994, Drug safety.

[316]  A. Kagey‐Sobotka,et al.  A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. , 1982, The Journal of allergy and clinical immunology.

[317]  A. Koivikko,et al.  A Double‐Blind, Multicenter Immunotherapy Trial in Children, Using a Purified and Standardized Cladosporium herbarum Preparation I. Clinical Results , 1986, Allergy.

[318]  D. Newton,et al.  House dust mite hyposensitization. , 1978, British journal of diseases of the chest.

[319]  S. Lebecque,et al.  Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. , 1990, The Journal of clinical investigation.

[320]  O. Osterballe.  Side effects during immunotherapy with purified grass pollen extracts. , 1982, Allergy.

[321]  M. Pain,et al.  Intranasal immunotherapy and polymerized grass pollen allergens. , 1982, Allergy.

[322]  P. Briza,et al.  Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. , 1997, International archives of allergy and immunology.

[323]  D. Marsh,et al.  Frequency of booster injections of allergoids. , 1990, The Journal of allergy and clinical immunology.

[324]  The use of standardized allergen extracts. American Academy of Allergy, Asthma and Immunology (AAAAI) , 1997, The Journal of allergy and clinical immunology.

[325]  G. Scadding,et al.  Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite , 1986, Clinical allergy.

[326]  H. Van Bever,et al.  Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). , 1992, The European respiratory journal.

[327]  C. Martínez-Cócera,et al.  A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy , 1996, Allergy.

[328]  W. Pierson,et al.  Beta-adrenergic blockers, immunotherapy, and skin testing , 1989 .

[329]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. , 1985, The Journal of allergy and clinical immunology.

[330]  L. Lichtenstein,et al.  A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. , 1980, The Journal of allergy and clinical immunology.

[331]  S. Durham,et al.  Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. , 1991, BMJ.

[332]  R. Valenta,et al.  Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. , 1994, The Journal of biological chemistry.

[333]  E. Juniper,et al.  Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. , 1990, The Journal of allergy and clinical immunology.

[334]  H. Løwenstein,et al.  The collaborative study of the international standard of dog, Canis domesticus, hair/dander extract. , 1988, The Journal of allergy and clinical immunology.

[335]  H. Sampson.  Food allergy and the role of immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[336]  T. Brennan,et al.  Patient noncompliance with medical advice after the emergency department visit. , 1996, Annals of emergency medicine.

[337]  R. Reisman,et al.  Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. , 1993, The Journal of allergy and clinical immunology.

[338]  R. Valenta,et al.  Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. , 1996, The Journal of allergy and clinical immunology.

[339]  G. Canonica,et al.  Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. , 1995, American journal of respiratory and critical care medicine.

[340]  J. Georgitis,et al.  Local intranasal immunotherapy for grass-allergic rhinitis. , 1983, The Journal of allergy and clinical immunology.

[341]  M. Mardiney,et al.  Dose response of IgE and IgG antibodies during ragweed immunotherapy. , 1984, The Journal of allergy and clinical immunology.

[342]  D. Tinkelman,et al.  Compliance with an allergen immunotherapy regime. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[343]  H. Malling,et al.  Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. , 1996, The Journal of allergy and clinical immunology.

[344]  J. Bousquet,et al.  Emergency treatment of allergic reactions to Hymenoptera stings , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[345]  S. Dreborg,et al.  Diagnosis and Immunotherapy of Mould Allergy , 1986, Allergy.

[346]  R. Valenta,et al.  Recombinant allergens for diagnosis and therapy of allergic diseases. , 1995, Current opinion in immunology.

[347]  R. Naclerio,et al.  Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. , 1991, The Journal of allergy and clinical immunology.

[348]  E. Pastorello,et al.  Clinical and immunological effects of immunotherapy with alum‐absorbed grass allergoid in grass‐pollen‐induced hay fever , 1992, Allergy.

[349]  P. Mayo,et al.  Results of a program to reduce admissions for adult asthma. , 1990, Annals of internal medicine.

[350]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. , 1989, The Journal of allergy and clinical immunology.

[351]  T. Gibson,et al.  THE CONTAMINATED DROP. , 1965, Lancet.

[352]  E. Gelfand,et al.  Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. , 1994, Journal of immunology.

[353]  L. Presta,et al.  The binding site on human immunoglobulin E for its high affinity receptor. , 1994, The Journal of biological chemistry.

[354]  A. Tabar,et al.  Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose‐titration study , 1997, Allergy.

[355]  V. Feliziani,et al.  Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. , 1995, Allergologia et immunopathologia.

[356]  C. Dolecek,et al.  Serological and skin‐test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[357]  R. Esch.  Role of proteases on the stability of allergenic extracts. , 1992, Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M.

[358]  R. N. Ross,et al.  Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. , 1988, Clinical therapeutics.